T 2397/11 (Erlotinib hydrochloride polymorph/HOFFMANN-LA ROCHE) of 15.10.2015
- European Case Law Identifier
- ECLI:EP:BA:2015:T239711.20151015
- Date of decision
- 15 October 2015
- Case number
- T 2397/11
- Petition for review of
- -
- Application number
- 04710031.8
- IPC class
- A61K 31/517C07D 239/94A61P 35/00
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- POLYMORPH OF {6,7-BIS(2-METHOXY-ETHOXY)-QUINAZOLIN-4-YL}-(3E)
- Applicant name
- F. Hoffmann-La Roche AG
- Opponent name
- Teva Pharmaceutical Industries LTD.
- Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 111(1)European Patent Convention Art 123(3)European Patent Convention Art 54European Patent Convention Art 84Rules of procedure of the Boards of Appeal Art 13(1)
- Keywords
- Clarity (yes)
Extension of protection conferred (no)
Novelty: main, auxiliary request 1 (no); auxiliary request 2 (yes)
Remittal, auxiliary request 2 - Catchword
- -
- Citing cases
- T 0200/20
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the department of first instance for further prosecution on the basis of the claims of auxiliary request 2 filed with letter dated 14 September 2015.